A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-D...
Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults .
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Galicia, Spain
Hospital Unviersitario Ramón y Cajal, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Ospedale San Raffaele, Milano, Italy
Northwestern University, Chicago, Illinois, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
M D Anderson Cancer Center, Houston, Texas, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.